Yes, semaglutide is FDA approved. It has been on the market since December 2017 and now comes in multiple brand names, formulations, and approved uses. The three main brand names are Ozempic, Rybelsus, and Wegovy, each approved for different conditions and patient populations.
Approved Brand Names and Dates
Semaglutide first received FDA approval as Ozempic, an injectable form for type 2 diabetes, on December 5, 2017. Two years later, on September 20, 2019, the FDA approved Rybelsus, the first oral tablet version of semaglutide, also for type 2 diabetes. Wegovy, an injectable form specifically for weight management, was approved on June 4, 2021.
More recently, the FDA has expanded the available formulations. A new oral version of Rybelsus was approved in December 2024, followed by Wegovy tablets in December 2025 and Ozempic tablets in January 2026. These newer tablet forms give patients alternatives to weekly injections.
What Semaglutide Is Approved to Treat
The FDA has approved semaglutide for several distinct uses, and the brand name matters because each one covers different conditions:
- Type 2 diabetes (Ozempic, Rybelsus): Approved to lower blood sugar in adults with type 2 diabetes, alongside diet and exercise.
- Weight management (Wegovy): Approved for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. In 2022, the FDA expanded Wegovy’s approval to include adolescents aged 12 and older with obesity.
- Cardiovascular risk reduction (Wegovy): In March 2024, the FDA approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who also have obesity or overweight. This made Wegovy the first weight management drug approved specifically to lower serious heart risks.
- Chronic kidney disease (Ozempic): Approved to lower the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
- Liver disease (Wegovy): Approved for metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease.
How Semaglutide Works
Semaglutide mimics a natural hormone called GLP-1 that your body releases after eating. Its structure is 94% identical to the human version of this hormone, but it’s been modified to last much longer in the body.
When semaglutide activates GLP-1 receptors in the pancreas, gut, and brain, several things happen. Your pancreas releases more insulin in response to rising blood sugar after meals, which is why it helps with diabetes. At the same time, it slows down how quickly food leaves your stomach, so you feel full longer. It also reduces the release of glucagon, a hormone that raises blood sugar.
The weight loss effects come largely from its action in the brain. Semaglutide interacts with appetite centers in the hypothalamus, reducing hunger, curbing food cravings, and increasing feelings of fullness. This combination of slower digestion and reduced appetite is what drives the significant weight loss seen with higher doses.
How It’s Taken
Injectable semaglutide (both Ozempic and Wegovy) is given as a once-weekly shot under the skin, on the same day each week, at any time of day, with or without meals. All versions start at a low dose of 0.25 mg per week for the first four weeks, then gradually increase. This slow ramp-up helps minimize side effects, particularly nausea. For weight management with Wegovy, the dose can go up to 7.2 mg per week at the highest level.
Oral tablets are taken daily rather than weekly. They need to be swallowed on an empty stomach with a small amount of plain water, then you wait at least 30 minutes before eating or drinking anything else. This is because food and liquid interfere with how the tablet gets absorbed.
Safety Warnings to Know About
Semaglutide carries the FDA’s most serious warning, called a boxed warning, related to thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors at doses similar to what humans take. Whether this translates to a real risk in people is still unknown, but the concern was significant enough for the FDA to flag it prominently.
Because of this warning, semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, trouble breathing, or persistent hoarseness while taking semaglutide, those are symptoms worth reporting to your doctor promptly. The FDA notes that routine thyroid screening with blood tests or ultrasounds hasn’t been shown to reliably catch problems early in people taking this medication.
Semaglutide is also contraindicated for anyone who has had a serious allergic reaction to it in the past.
Compounded Semaglutide Is Not FDA Approved
An important distinction: compounded versions of semaglutide, which became widely available during brand-name shortages, are not FDA approved. The FDA has been clear that compounded drugs do not go through the same rigorous review for safety, effectiveness, and quality that brand-name products undergo.
As supply of the brand-name products has stabilized, the FDA has tightened its stance. Semaglutide no longer appears on the FDA’s drug shortage list, which limits the legal basis for compounding pharmacies to produce it. The FDA has also clarified that adding another ingredient like vitamin B12 to compounded semaglutide does not make it a meaningfully different product, so compounders generally cannot use that as a workaround. The agency has signaled it may take enforcement action against compounded products that are substandard in quality or otherwise unsafe.
If you’re currently using a compounded version, it’s worth knowing that its purity, potency, and sterility have not been independently verified by the FDA, which is a real difference from the approved brand-name products.